Da­ta to dol­lars: Geron sells stock to raise over $200M af­ter PhI­II read­out on MDS drug

Fol­low­ing a Phase III read­out last week on its blood can­cer drug, Geron has raised about $213 mil­lion via a pub­lic of­fer­ing.

The mon­ey will go to­ward prepar­ing for a po­ten­tial launch for its drug, ime­tel­stat, in low-risk myelodys­plas­tic syn­dromes, or MDS, the pa­tient pop­u­la­tion of the Phase III tri­al, ac­cord­ing to Geron’s press re­lease Tues­day af­ter­noon. In­clud­ing the un­der­writ­ers’ pur­chase of ad­di­tion­al shares of com­mon stock, Geron sold 68 mil­lion shares of com­mon stock at $2.45 and pre-fund­ed war­rants for 25 mil­lion shares at $2.449.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER